Patients with psoriasis are at increased risk for psychiatric comorbidities, including suicidal ideation and behavior. For this reason, a careful assessment of patients, in particular for those reporting history of psychiatric symptoms is needed. We herein report a case series of 3 patients affected by major psychiatric disorders and moderate-to-severe psoriasis, successfully treated with secukinumab, an IL17A inhibitor, with a long-term psychiatric disease stability.
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series
Esposito, Maria
;Fargnoli, Maria Concetta
2020-01-01
Abstract
Patients with psoriasis are at increased risk for psychiatric comorbidities, including suicidal ideation and behavior. For this reason, a careful assessment of patients, in particular for those reporting history of psychiatric symptoms is needed. We herein report a case series of 3 patients affected by major psychiatric disorders and moderate-to-severe psoriasis, successfully treated with secukinumab, an IL17A inhibitor, with a long-term psychiatric disease stability.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Esposito Postgraduate Medicine 2020_Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders .pdf
solo utenti autorizzati
Tipologia:
Documento in Pre-print
Licenza:
Dominio pubblico
Dimensione
1.38 MB
Formato
Adobe PDF
|
1.38 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
00325481.2020.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
Dominio pubblico
Dimensione
1.05 MB
Formato
Adobe PDF
|
1.05 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.